Senseonics Reports 140% Year-Over-Year Revenue Growth in Q3 2026
Senseonics Holdings, Inc. (SENS) reported strong third-quarter 2026 financial results, headlined by a 140% year-over-year revenue increase to $19.6 million. This growth was primarily fueled by record new patient starts in the U.S., where revenue surged 160%. The company also saw significant gross margin expansion, reaching 62% compared to 43% in the same period last year. Driven by this momentum, management raised its full-year revenue guidance to a range of $68 million to $70 million and increased its gross margin outlook to over 60%. While net losses widened to $32.7 million due to increased R&D and SG&A expenses related to clinical trials and commercial expansion, the company provided an optimistic 2027 revenue outlook of $100 million.
Topics: clinical trials gross margin expansion guidance raise net loss revenue growth